Switch theme
Sign up to access all valuation multiples
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics.
1981
11.1K+
LTM Revenue $944M
LTM EBITDA $178M
$3.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Emcure Pharmaceuticals has a last 12-month revenue (LTM) of $944M and a last 12-month EBITDA of $178M.
In the most recent fiscal year, Emcure Pharmaceuticals achieved revenue of $925M and an EBITDA of $179M.
Emcure Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Emcure Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $944M | XXX | $925M | XXX | XXX | XXX |
| Gross Profit | $569M | XXX | $556M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | $178M | XXX | $179M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $133M | XXX | $127M | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $85.8M | XXX | $79.8M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $67.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Emcure Pharmaceuticals's stock price is INR 1330 (or $16).
Emcure Pharmaceuticals has current market cap of INR 252B (or $3.0B), and EV of INR 259B (or $3.0B).
See Emcure Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.0B | $3.0B | XXX | XXX | XXX | XXX | $0.45 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Emcure Pharmaceuticals has market cap of $3.0B and EV of $3.0B.
Emcure Pharmaceuticals's trades at 3.4x EV/Revenue multiple, and 17.7x EV/EBITDA.
Equity research analysts estimate Emcure Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Emcure Pharmaceuticals has a P/E ratio of 34.4x.
See valuation multiples for Emcure Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | 17.1x | XXX | 17.7x | XXX | XXX | XXX |
| EV/EBIT | 22.9x | XXX | 24.6x | XXX | XXX | XXX |
| EV/Gross Profit | 5.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 34.4x | XXX | 39.7x | XXX | XXX | XXX |
| EV/FCF | 90.7x | XXX | 48.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEmcure Pharmaceuticals's last 12 month revenue growth is 12%
Emcure Pharmaceuticals's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $39K for the same period.
Emcure Pharmaceuticals's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Emcure Pharmaceuticals's rule of X is 50% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Emcure Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | 15% | XXX | XXX | XXX |
| Rule of 40 | 32% | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 50% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $39K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Emcure Pharmaceuticals acquired XXX companies to date.
Last acquisition by Emcure Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Emcure Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Emcure Pharmaceuticals founded? | Emcure Pharmaceuticals was founded in 1981. |
| Where is Emcure Pharmaceuticals headquartered? | Emcure Pharmaceuticals is headquartered in India. |
| How many employees does Emcure Pharmaceuticals have? | As of today, Emcure Pharmaceuticals has 11.1K+ employees. |
| Is Emcure Pharmaceuticals publicy listed? | Yes, Emcure Pharmaceuticals is a public company listed on BOM. |
| What is the stock symbol of Emcure Pharmaceuticals? | Emcure Pharmaceuticals trades under 544210 ticker. |
| When did Emcure Pharmaceuticals go public? | Emcure Pharmaceuticals went public in 2024. |
| Who are competitors of Emcure Pharmaceuticals? | Similar companies to Emcure Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Emcure Pharmaceuticals? | Emcure Pharmaceuticals's current market cap is $3.0B |
| What is the current revenue of Emcure Pharmaceuticals? | Emcure Pharmaceuticals's last 12 months revenue is $944M. |
| What is the current revenue growth of Emcure Pharmaceuticals? | Emcure Pharmaceuticals revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Emcure Pharmaceuticals? | Current revenue multiple of Emcure Pharmaceuticals is 3.2x. |
| Is Emcure Pharmaceuticals profitable? | Yes, Emcure Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Emcure Pharmaceuticals? | Emcure Pharmaceuticals's last 12 months EBITDA is $178M. |
| What is Emcure Pharmaceuticals's EBITDA margin? | Emcure Pharmaceuticals's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Emcure Pharmaceuticals? | Current EBITDA multiple of Emcure Pharmaceuticals is 17.1x. |
| What is the current FCF of Emcure Pharmaceuticals? | Emcure Pharmaceuticals's last 12 months FCF is $33.5M. |
| What is Emcure Pharmaceuticals's FCF margin? | Emcure Pharmaceuticals's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Emcure Pharmaceuticals? | Current FCF multiple of Emcure Pharmaceuticals is 90.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
